Rick Hawkins is Chief Executive Officer of Lumos Pharma. Previously, Mr. Hawkins founded Pharmaco and as Chairman, President and Chief Executive Officer, he managed the growth of that organization to over 700 employees. Pharmaco offered a full range of clinical drug development services to the pharmaceutical industry, including Phase I-IV clinical trials and analytical chemistry services. The company merged with Applied Bioscience International. Mr. Hawkins managed their 2000 employee international Research & Development operations. Pharmaco merged with PPD of Wilmington, NC to form PPD Pharmaco, one of the largest clinical contract research organizations in the world.
After selling Pharmaco, Mr. Hawkins founded id2, a pharmaceutical and biotechnology research management company. Through his position as Chairman and CEO at id2, he has served as an advisor and mentor in the start-up of numerous companies, including Sensus Drug Development Corporation. Sensus, a biotechnology company, developed a Growth Hormone Antagonist for use in acromegaly, the complications of diabetes, and regulation of growth hormone in the treatment of specific types of tumors. Mr. Hawkins co-founded Sensus and served as the Chairman. Sensus was sold to Pharmacia (now Pfizer).
In addition to Sensus, Mr. Hawkins was co-founder and Director of Covance Biotechnology Services, Inc., a full-service contract manufacturer of recombinant proteins located in Research Triangle Park, NC. Covance Biotechnology Services was sold to Akzo Nobel, Inc in early 2001. Mr. Hawkins co-founded and acted as CEO, President, and Chairman of LabNow, a diagnostic device company established to improve the quality of patient care and lower overall treatment costs through deployment of rapid, point-of-care, physician office-based diagnostic testing systems.
Mr. Hawkins currently serves as a Director for Plus Therapeutics (PSTV) and Savara Pharmaceuticals (SVRA).
Mr. Hawkins was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas. In 2006 he received Ohio University’s Distinguished Business Achievement Award and was named on the top 10 Life Sciences CEO’s in Texas by the Texas Healthcare & Bioscience Institute. He is a member of the National Ernst and Young Entrepreneur of the Year Hall of Fame. In 2015, he received Ohio University’s Konneker Medal, the highest award given to a faculty member or former student for entrepreneurial excellence. Mr. Hawkins resides in Austin, Texas and maintains a residence near Columbus, Ohio.
Mr. Hawkins has served on the Lumos Pharma Board since 2012.
Carl Langren is the Chief Financial Officer of Lumos Pharma. He brings over 13 years of public company executive experience in biotechnology, including finance, federal contracting, information systems, compliance, and operations. Prior to the merger with Lumos Pharma, he served as the Chief Financial Officer at NewLink Genetics Corporation. Mr. Langren has enjoyed a career in management and finance that has included positions in venture capital, manufacturing, distribution and public accounting.
Mr. Langren joined NewLink Genetics in 2011 and served as Vice President, Finance until his promotion to Chief Financial Officer in 2018. Prior to NewLink, Mr. Langren was the Chief Financial Officer of BioProtection Systems Corporation, a wholly owned subsidiary of NewLink Genetics. BioProtection Systems focused on the research, development and commercialization of vaccines to control the spread of emerging infectious diseases, improvement in the efficacy of existing vaccines and providing rapid-response prophylactic and therapeutic treatment for pathogens most likely to enter the human population through pandemics or acts of bioterrorism.
Prior to BioProtection Systems, Mr. Langren was Chief Financial Officer of Housby Mixer Group, where he managed financial development and the creation of an e-commerce system for a three-tier distribution channel. Before that, as President of Iowa Machinery and Supply, a distribution company, he facilitated a fivefold increase in equity and near doubling of revenues by focusing on customer needs, reorganizing operating divisions and expanding geographic coverage.
Mr. Langren began his career as an auditor at McGladrey. Mr. Langren received a BA in accounting, with highest distinction, from the University of Iowa.
Eugene P. Kennedy, MD, FACS, has served as Lumos Pharma and previously NewLink Genetics CMO since November 2017. Prior to that, he served as Vice President for Clinical and Medical Affairs since 2014, having joined NewLink in 2013. With NewLink, Dr. Kennedy has been responsible for the design, implementation, and execution of more than a dozen clinical trials ranging from multiple first in human studies through Phase 3 while overseeing a total of more than 20 studies across 11 product candidates in addition to multiple investigator-initiated efforts.
Prior to joining NewLink Genetics, Dr. Kennedy was on faculty and clinical staff at Thomas Jefferson University in Philadelphia, PA where he served as Associate Professor of Surgery. During his time at Jefferson, he built a clinical and translational research program focused on the treatment of pancreatic cancer, launching both internally and externally sponsored trials while building the infrastructure to support both. Dr. Kennedy held leadership positions as Chief of the Section of Pancreaticobiliary Surgery and Co-Director of the Jefferson Pancreas, Biliary, and Related Cancers Center from January 2006 to December 2013. He served the institution as the Chair of the Data Safety Monitoring Committee for the Sidney Kimmel Cancer Center at Jefferson in addition to other positions and his patient care and teaching responsibilities. Previously, Dr. Kennedy held faculty appointments at the Johns Hopkins Hospital in Baltimore, MD and the Louisiana State University School of Medicine in New Orleans, LA.
Dr. Kennedy received a B.A. degree as an Echols Scholar from the University of Virginia in Charlottesville, VA and a M.D. degree with honors (Alpha Omega Alpha) from the Medical College of Virginia in Richmond, VA. He obtained his General Surgical residency and Surgical Oncology fellowship training at the Johns Hopkins School of Medicine in Baltimore, MD along with a post-doctoral fellowship in immuno-oncology at Johns Hopkins and surgical training at the Royal College of Surgeons in Ireland School of Medicine Beaumont Hospital in Dublin, Ireland. He has over 50 peer-reviewed publications as well as numerous book chapters, reviews, and abstracts.
Dr. Kennedy has served for over 10 years as a Trustee of the Hope Funds for Cancer Research whose mission is focused on the investigation of innovative cancer treatment and detection for the most difficult-to-treat and understudied cancers.
John McKew is Chief Scientific Officer of Lumos Pharma. Dr. McKew has spent the last 27 years developing novel therapeutics. He has successfully moved therapeutics through pre-clinical and into clinical development in publicly traded biotech, large pharma, government labs, and privately held biotech companies. Dr. McKew was head of research at aTyr Pharma where he led a research team discovering and advancing protein-based therapeutics for rare diseases. Dr. McKew was also the Acting Scientific Director of the National Center for Advancing Translational Science (NCATS) intramural group where he was responsible for scientific efforts ranging from high throughput screening and in vitro toxicology efforts, through translational efforts for novel therapeutic candidates. Dr. McKew’s lab focused on developing two drug discovery programs, Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs) where projects are advanced using novel public/private partnerships. The team’s expertise spanned pre-clinical and IND enabling data generation to first in human and observational studies at the NIH clinical center. Several innovative therapies that were collaboratively advanced through these programs are now being commercialized by pharmaceutical companies (i.e. VTS-270 for Niemann-Pick disease). Before joining the NIH, Dr. McKew held a Director level position at Wyeth Research in Cambridge, Massachusetts. At Wyeth Research he led a variety of research initiatives including a hit-to-lead chemistry group which supported cardiovascular, musculoskeletal and metabolic disease therapeutic areas. He began his professional career at Genetics Institute, Inc., where he worked on translating novel inflammation targets into clinical candidates.
In addition to his work with Lumos Pharma, Dr. McKew is currently an Adjunct Associate Professor at the Boston University School of Medicine. He has also served as the Chair Elect, Chair and Immediate Past Chair of the American Chemical Society’s Northeastern section. Dr. McKew also participates in multiple special emphasis panels (SEP) (NCI NeXT, CPRIT, AND NCI SBIR advisory panel) He has over 60 peer-reviewed publications and granted patents. Dr. McKew graduated from State University of New York at Stony Brook with B.S. degrees in Chemistry and Biochemistry, completed his Ph.D. in Organic Chemistry at University of California, Davis and held post-doctoral research positions at the University of Geneva and Firmenich, SA.
Dr. McKew currently resides on a small organic farm in the Agricultural Reserve of Montgomery County Maryland.
Aaron Schuchart has over twenty years of experience in key leadership roles for both large multinationals and small biotech companies, including Amgen, Novartis Diagnostics/Grifols, and Coherus Biosciences. Recently, as Chief Business Officer of Aeglea BioTherapeutics, Mr. Schuchart led the Business Development, Commercial Planning, and Intellectual Property functions to build an integrated, late stage company based on a protein engineering platform with utility in rare disease and cancer. Throughout his tenure in the industry, Mr. Schuchart has led or advised on over 30 transactions totaling over $15 billion; developed and executed portfolio strategies for various technology platforms, therapeutic areas and markets toward the achievement of strong operating and financial growth performance for biopharmaceuticals and diagnostics businesses.
Mr. Schuchart received a B.B.A. in Accounting from Texas Tech University and an M.B.A. from UCLA Anderson School of Management. He is a Certified Licensing Professional and is licensed as a Certified Public Accountant.
Brad Powers is the General Counsel of Lumos Pharma. Prior to the merger with Lumos Pharma, he served as General Counsel at NewLink Genetics where he was directly responsible for all legal matters including corporate transactions, risk management, intellectual property, compliance, regulatory affairs, human resources, quality assurance and business development activities. As member of the senior management team, he helped develop corporate strategy and communications with board of directors, investors, and stakeholders. Prior to joining NewLink Genetics, Mr. Powers served as General Counsel and Interim Director of Global Sales, Service and Marketing at Kinze Manufacturing, Inc., a privately held, international agricultural manufacturer. Before that, he held senior legal positions at McKee, Voorhees and Sease, Iowa’s largest Intellectual Property boutique firm where he managed patent litigation, intellectual property licensing, and trademark protection. During his time at Iowa State University and Drake University School of Law, Mr. Powers also worked as the Director of Information Technology at NewLink Genetics.
Mr. Powers graduated from Iowa State University with a master’s degree in Bioinformatics and Computational Biology and a bachelor’s degree in Biology. He earned a juris doctor degree from Drake University School of Law. Mr. Powers is a registered US patent attorney and is licensed to practice law before Iowa’s State and Federal Courts, the 8th Circuit Court of Appeals, the Federal Circuit Court of Appeals and the United States Patent and Trademark Office.
Lori Lawley is the Senior Vice President of Finance and Controller at Lumos Pharma. She brings over ten years of experience and accounting expertise in overseeing financial operations. Ms. Lawley is responsible for all aspects of the Company’s accounting and financial reporting functions – including SEC reporting, technical accounting, budgeting and forecasting, and financial systems implementation. Ms. Lawley is also responsible for ensuring we have the proper procedures and controls in place for effective internal controls over financial reporting. Prior to the merger with Lumos Pharma, she held various senior roles of increasing responsibility in NewLink’s finance department, including Corporate Controller, Director Financial and SEC Reporting, and most recently as Vice President of Finance and Controller. Before joining NewLink, Ms. Lawley served as Senior Manager, Assurance and Advisory Business Services at Ernst & Young. There Ms. Lawley oversaw teams through the planning and completion of integrated and non-integrated audits of financial statements within both the public and private sectors.
Ms. Lawley is a licensed certified public accountant. She earned a BBA in Accounting and a master’s degree in Professional Accounting from The University of Texas at Austin, Red McCombs School of Business.
Stock transaction information provided by EDGAR Online. Lumos Pharma makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating, or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.